SillaJen, Inc. (215600.KQ) KOE
Currency In KRW
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
SillaJen, Inc.
Sector
Healthcare
Industry
Biotechnology
Employees
43
First IPO Date
December 06, 2016
Key Executives
| Name | Title | Pay | Year Born |
| Jaekyung Kim | Chief Executive Officer & Chairman of the Board | 0 | 1964 |
| Jeongseok Lee | Executive Officer | 0 | 1982 |
| SeungHwan Cho | Executive Officer | 0 | 1978 |
| TaeGyun Kim | President | 0 | 1963 |
| SangGeun Park | Executive Director | 0 | 1976 |
| Mee Yang Kyung | Head of R&D Strategic Planning | 0 | N/A |
| Eun-Ki Min | Chief Accounting Officer and Executive Director | 0 | N/A |
| Suk Song Myung | Chief Financial Officer | 0 | N/A |
| Chan Kwon Hyuk | Chief Medical Officer | 0 | N/A |
| Jaejeong Lee | Executive Officer | 0 | 1971 |
AD
Description
SillaJen, Inc. is dedicated to the advancement and commercialization of oncolytic immunotherapy products. Its primary therapeutic candidate, Pexa-Vec, is currently undergoing Phase II clinical evaluation as a potential treatment for late-stage liver cancer. The firm also has JX-970 in development, aimed at targeting tumor tissues, and the JX-900 series, which consists of modified vaccinia vaccines. Established in 2006, SillaJen is headquartered in Seoul, South Korea.
AD
